Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-Analysis
Levodopa (L-dopa) and catechol-O-methyltransferase (COMT) inhibition are widely used therapeutics in Parkinson’s disease (PD). Despite their therapeutic effects, it was raised that nutrients involved in one-carbon metabolism can be deteriorated by PD therapies. The aim of this meta-analysis was to i...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/15/4/901 |
| _version_ | 1797618870375153664 |
|---|---|
| author | Jin Hee Kim Shaoyue Jin Hyeyoon Eo Myung Sook Oh Yunsook Lim |
| author_facet | Jin Hee Kim Shaoyue Jin Hyeyoon Eo Myung Sook Oh Yunsook Lim |
| author_sort | Jin Hee Kim |
| collection | DOAJ |
| description | Levodopa (L-dopa) and catechol-O-methyltransferase (COMT) inhibition are widely used therapeutics in Parkinson’s disease (PD). Despite their therapeutic effects, it was raised that nutrients involved in one-carbon metabolism can be deteriorated by PD therapies. The aim of this meta-analysis was to investigate the impact of L-dopa and COMT inhibitors on levels of homocysteine (Hcy), vitamin B<sub>12</sub> and folate in patients with PD. A total of 35 case-control studies from 14 different countries were selected through PubMed, MEDLINE and Google Scholar and were meta-analyzed. In the L-dopa group, the Hcy level was higher compared to the PD without L-dopa group (SMD: 5.11 μmol/L, 95% CI: 3.56 to 6.66). Moreover, vitamin B<sub>12</sub> and folate levels in the L-dopa group were lower compared to the healthy control (SMD: −62.67 pg/mL, 95% CI: −86.53 to −38.81; SMD: −0.89 ng/mL, 95% CI: −1.44 to −0.33, respectively). The COMT inhibitor group showed lower levels of Hcy (SMD: −3.78 μmol/L, 95% CI: −5.27 to −2.29) and vitamin B<sub>12</sub> (SMD: −51.01 pg/mL, 95% CI: −91.45 to −10.57), but higher folate levels (SMD: 1.78 ng/mL, 95% CI: −0.59 to 4.15) compared to the L-dopa group. COMT inhibitors may ameliorate L-dopa-induced hyper-homocysteine and folate deficiency but exacerbate vitamin B<sub>12</sub> deficiency. |
| first_indexed | 2024-03-11T08:19:41Z |
| format | Article |
| id | doaj.art-2e2b9742fed548d5ab85c6e16cb97d1a |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-11T08:19:41Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-2e2b9742fed548d5ab85c6e16cb97d1a2023-11-16T22:30:31ZengMDPI AGNutrients2072-66432023-02-0115490110.3390/nu15040901Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-AnalysisJin Hee Kim0Shaoyue Jin1Hyeyoon Eo2Myung Sook Oh3Yunsook Lim4Department of Biomedical and Pharmaceutical Science, Kyung Hee University, Seoul 02447, Republic of KoreaSchool of Medicine, Ningbo University, Ningbo 315211, ChinaDepartment of Biomedical and Pharmaceutical Science, Kyung Hee University, Seoul 02447, Republic of KoreaDepartment of Biomedical and Pharmaceutical Science, Kyung Hee University, Seoul 02447, Republic of KoreaDepartment of Food and Nutrition, Graduate School, Kyung Hee University, Seoul 02447, Republic of KoreaLevodopa (L-dopa) and catechol-O-methyltransferase (COMT) inhibition are widely used therapeutics in Parkinson’s disease (PD). Despite their therapeutic effects, it was raised that nutrients involved in one-carbon metabolism can be deteriorated by PD therapies. The aim of this meta-analysis was to investigate the impact of L-dopa and COMT inhibitors on levels of homocysteine (Hcy), vitamin B<sub>12</sub> and folate in patients with PD. A total of 35 case-control studies from 14 different countries were selected through PubMed, MEDLINE and Google Scholar and were meta-analyzed. In the L-dopa group, the Hcy level was higher compared to the PD without L-dopa group (SMD: 5.11 μmol/L, 95% CI: 3.56 to 6.66). Moreover, vitamin B<sub>12</sub> and folate levels in the L-dopa group were lower compared to the healthy control (SMD: −62.67 pg/mL, 95% CI: −86.53 to −38.81; SMD: −0.89 ng/mL, 95% CI: −1.44 to −0.33, respectively). The COMT inhibitor group showed lower levels of Hcy (SMD: −3.78 μmol/L, 95% CI: −5.27 to −2.29) and vitamin B<sub>12</sub> (SMD: −51.01 pg/mL, 95% CI: −91.45 to −10.57), but higher folate levels (SMD: 1.78 ng/mL, 95% CI: −0.59 to 4.15) compared to the L-dopa group. COMT inhibitors may ameliorate L-dopa-induced hyper-homocysteine and folate deficiency but exacerbate vitamin B<sub>12</sub> deficiency.https://www.mdpi.com/2072-6643/15/4/901meta-analysisParkinson’s diseaseone-carbon metabolismlevodopahomocysteinevitamin B |
| spellingShingle | Jin Hee Kim Shaoyue Jin Hyeyoon Eo Myung Sook Oh Yunsook Lim Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-Analysis Nutrients meta-analysis Parkinson’s disease one-carbon metabolism levodopa homocysteine vitamin B |
| title | Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-Analysis |
| title_full | Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-Analysis |
| title_fullStr | Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-Analysis |
| title_full_unstemmed | Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-Analysis |
| title_short | Two Faces of Catechol-O-Methyltransferase Inhibitor on One-Carbon Metabolism in Parkinson’s Disease: A Meta-Analysis |
| title_sort | two faces of catechol o methyltransferase inhibitor on one carbon metabolism in parkinson s disease a meta analysis |
| topic | meta-analysis Parkinson’s disease one-carbon metabolism levodopa homocysteine vitamin B |
| url | https://www.mdpi.com/2072-6643/15/4/901 |
| work_keys_str_mv | AT jinheekim twofacesofcatecholomethyltransferaseinhibitorononecarbonmetabolisminparkinsonsdiseaseametaanalysis AT shaoyuejin twofacesofcatecholomethyltransferaseinhibitorononecarbonmetabolisminparkinsonsdiseaseametaanalysis AT hyeyooneo twofacesofcatecholomethyltransferaseinhibitorononecarbonmetabolisminparkinsonsdiseaseametaanalysis AT myungsookoh twofacesofcatecholomethyltransferaseinhibitorononecarbonmetabolisminparkinsonsdiseaseametaanalysis AT yunsooklim twofacesofcatecholomethyltransferaseinhibitorononecarbonmetabolisminparkinsonsdiseaseametaanalysis |